Advisers to the U.S. Food and Drug
Administration on Thursday unanimously backed the use of updated
COVID-19 vaccines that would target an XBB Omicron subvariant of
the coronavirus for the 2023-2024. | June 15, 2023
By Colin Kellaher The U.S. Food and Drug Administration on Thursday said it granted full approval to Pfizer s Paxlovid for high-risk adults, paving the way for the drugmaker to sell the oral. | May 25, 2023
Pfizer Inc Chief
Executive Albert Bourla on Thursday called U.S. plans to
negotiate drug prices for its Medicare health program
negotiation with a gun to your head and said he expects
drugmakers to. | May 11, 2023
PFIZER SAYS U.S. GOVERNMENT PURCHASE SUPPLEMENTS 20 MLN TREATMENT COURSES PREVIOUSLY CONTRACTED BY AND ALREADY DELIVERED TO THE U.S. GOVERNMENT . | December 13, 2022
By Colin Kellaher Pfizer Inc. on Tuesday reported mixed results from a Phase 3 study of PF-06425090, its vaccine candidate for the prevention of C. difficile infection, or CDI. The New. | March 1, 2022